BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 4, 2026
Home » Blogs » BioWorld MedTech Perspectives » Congress doffs the hat to Alzheimer's, but where's the money?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Congress doffs the hat to Alzheimer's, but where's the money?

June 30, 2011
By Mark McCarty

Washington is such a fun town, replete as it is with smoke and mirrors. It appears that despite my earlier protests about the mixed-up priorities where NIH spending are concerned, our elected officials are aware of the coming deluge of costs associated with Alzheimer's disease, but the latest legislation to address this disease, the National Alzheimer's Project Act (which goes by the cheery acronym of NAPA for you fans of wine and/or auto parts stores) seems to do little other than coordinate federal and state resources.

According to a fact sheet posted at the website for the Alzheimer's Association (AA; Chicago) the legislation, which President Obama signed into law in January, won a unanimous vote in both the House and the Senate. A cynic's guide to Capitol Hill tells you two things about a vote like that. One is that Congress has yet to wean itself off the mother's milk of feel-good votes for patient groups, and two is that the bill demands little or nothing (nothing, a.k.a, diddlysquat, squadoosh and so on) in the way of resources. Had the bill cost a single thin dime, it would have drawn at least one nay vote, especially in this economic climate.

But as I stated in my two posts (here and here) to the MDD Perspectives blog on NIH's finances, spending on heart disease and Alzheimer's relative to NIH spending on cancer is strangely low when you consider the relative burdens these diseases impose on society. Consider that and then read the undated statement at the AA website about NAPA. The legislation “will create a coordinated national plan to overcome the Alzheimer crisis and will ensure the coordination and evaluation of all national efforts in Alzheimer research, clinical care, institutional, and home- and community-based programs and their outcomes,” the statement claims.

The absence of any meaningful commitment by our government (by which I mean our tax dollars) is just a wee bit conspicuous. I can just hear the legendary Clara Peller hollering “where's the beef?” Her feigned outrage over the skimpy portions of beef on burgers was hilarious, but I can just imagine what a member of our nation's electoral elite would say in response.

“We're sorry Mrs. Peller, what on earth makes you think a hamburger has to have beef to be a burger? It's called a HAMburger, not a beefburger!”

It's too bad both Mrs. Peller and Dave Thomas, the founder of Wendy's, the fast-food chain that made the dear lady famous, aren't around to ask our elected officials where in heck the money is (Mrs. Peller) and to do something about the absence of any meaningful additional resources for Alzheimer's (Mr. Thomas). This would be funny as screwball comedy but for one thing: Human lives and our nation's economy are at stake. That's not funny, not even a little bit.

It's another example of why the process of making policy, like the process of making sausage, is simply horrible to behold. But as we all know, there's often little or no digestible beef in sausage.

Something's missing!

 

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 2, 2026.
  • Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

    Small-molecule TREM2 agonist advances to treat Alzheimer’s

    BioWorld Science
    Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
  • Amyloid beta peptides on neurons

    Amlogenyx’s AM-805 reduces amyloid plaques in AD

    BioWorld Science
    The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • Atai Therapeutics patents new 5-HT2 receptor agonists

    BioWorld Science
    Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing